3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
21
Prostatic Neoplasms, Castration-Resistant
2
Metastatic Castration-resistant Prostate Cancer
2
Urogenital Neoplasms
1
Thrombocytopenia
1
Prostatic Diseases
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Neoplasms by Site
1
Neoplasms
1
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1
Male Urogenital Diseases
1
Liver Neoplasms
1
Kidney Neoplasms
1
High-Risk Localized Prostate Cancer
1
Glioma
1
Glioblastoma
1
Genital Neoplasms, Male
1
Disease
1
Cytopenia
1
Clear-cell metastatic renal cell carcinoma
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Astrocytoma
1
Anemia
1
Interventions
olaparib
3
enzalutamide
2
darolutamide
2
Prednisone
2
Prednisolone
2
Pluvicto
2
Docetaxel
2
Androgen Antagonists
2
Abiraterone Acetate
2
testosterone 17 beta-cypionate
1
radium Ra 223 dichloride
1
fludarabine phosphate
1
fludarabine
1
cabazitaxel
1
alovudine
1
abiraterone
1
Standard of Care
1
Radium-223
1
PSMA-617
1
Nivolumab
1
Gonadotropin-Releasing Hormone
1
Cyclophosphamide
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Metastatic Castration-resistant Prostate Cancer
×
Pluvicto
×
90 days
×
Clear all
NCT06514521
2026-06-01
Post Marketing Study on Pluvicto in Korea
Novartis
Recruiting
278 enrolled
NCT05682443
2026-05-22
PRESERVE-006
OncoC4, Inc.
Phase 1/2
Active not recruiting
148 enrolled